Abstract
Screening tests conducted at rest may be inadequate for the prediction of the T-wave oversensing (TWOS) in subcutaneous implantable cardioverter defibrillator (S-ICD) candidates with Brugada syndrome (BrS) because of the dynamic nature of electrocardiogram (ECG) morphology. We evaluated the utility of ECG screening during drug challenge (DC) for prediction of TWOS in BrS patients implanted with an S-ICD. The study enrolled 6 consecutive BrS patients implanted with an S-ICD. In addition to baseline ECG screening, pre-implant screening during DC using a sodium channel blocker was performed in all patients. All patients underwent appropriate morphological analysis on baseline ECG screening; however, 2 BrS patients (33%) showed inappropriate sensing during DC. During 243 days of follow-up after S-ICD implantation, no patient experienced an appropriate shock. TWOS was confirmed during exercise testing in one of 2 patients who showed inappropriate sensing during DC. However, one patient with appropriate sensing during DC experienced recurrent episodes of inappropriate shocks due to TWOS during exercise. The present initial experience indicates that further studies are needed to detect the risk for TWOS from an S-ICD in BrS patients.
This is a preview of subscription content, log in via an institution to check access.
References
Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, Marquie C, Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field ME, Derval N, Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB, Ploux S, Rollin A, Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jaïs P, Pasquié JL, Hocini M, Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P, Haïssaguerre M (2013) Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation 128:1739–1747
Kamakura T, Wada M, Nakajima I, Ishibashi K, Miyamoto K, Okamura H, Noda T, Aiba T, Takaki H, Yasuda S, Ogawa H, Shimizu W, Makiyama T, Kimura T, Kamakura S, Kusano K (2015) Evaluation of necessity for cardioverter-defibrillator implantation in elderly patients with Brugada syndrome. Circ Arrhythm Electrophysiol 8:785–791
Burke MC, Gold MR, Knight BP, Barr CS, Theuns DA, Boersma LV, Knops RE, Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD (2015) Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 65:1605–1615
Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB, Hood M, Pedersen S, Kääb S, Murgatroyd F, Reeve HL, Carter N, Boersma L, Investigators EFFORTLESS (2014) Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 35:1657–1665
Kamakura T, Sato T, Wada M, Ishibashi K, Noda T, Kusano K (2016) T-wave oversensing during drug challenge test after subcutaneous implantable cardioverter-defibrillator implantation in a patient with Brugada syndrome. Heart Rhythm Case Rep 2:391–394
Conte G, Regoli F, Moccetti T, Auricchio A (2016) Subcutaneous implantable cardioverter-defibrillator and drug-induced Brugada syndrome: the importance of repeat morphology analysis during ajmaline challenge. Eur Heart J 37:1498
Olde Nordkamp LR, Conte G, Rosenmöller BR, Warnaars JL, Tan HL, Caputo ML, Regoli F, Moccetti T, Auricchio A, Knops RE, Wilde AA (2016) Brugada syndrome and the subcutaneous implantable cardioverter-defibrillator. J Am Coll Cardiol 68:665–666
Sakamoto S, Takagi M, Tatsumi H, Doi A, Sugioka K, Hanatani A, Yoshiyama M (2016) Utility of T-wave alternans during night time as a predictor for ventricular fibrillation in patients with Brugada syndrome. Heart Vessels 31:947–956
Sakamoto S, Takagi M, Kakihara J, Hayashi Y, Doi A, Sugioka K, Yoshiyama M (2017) The utility of T-wave alternans during the morning in the summer for the risk stratification of patients with Brugada syndrome. Heart Vessels 32:341–351
Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, ShimizuW Tomaselli G, Tracy C (2013) HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10:1932–1963
Antzelevitch C, Brugada P, Borgreffe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A (2005) Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111:659–670
Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA, de Groot JR (2014) Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. Heart Rhythm 11:426–434
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Funding
This work was supported by a grant from Suzuken Memorial Foundation, and intramural research funds (27-6-8) for cardiovascular disease from the National Cerebral and Cardiovascular Center.
Rights and permissions
About this article
Cite this article
Kamakura, T., Wada, M., Ishibashi, K. et al. Impact of electrocardiogram screening during drug challenge test for the prediction of T-wave oversensing by a subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. Heart Vessels 32, 1277–1283 (2017). https://doi.org/10.1007/s00380-017-0994-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-017-0994-3